Theratechnologies Inc (TSX:TH) (OTCMKTS:THERF), a specialty pharmaceutical company, announced Wednesday that the Chinese facility set to manufacture its HIV drug received the necessary certification from Europe.
Trogarzo is an antiretroviral drug used to treat patients with multidrug-resistant HIV-1 infection.
Shares of Montreal-based Theratechnologies closed up 9.3% to C$7.56 in Canada and advanced 9.8% to US$5.69 on the OTC Markets.
Manufacturing is set to take place at the Wuxi Biologics facilities in Wuxi City and Shanghai, both in China. The European Medicines Agency granted the facilities the Good Manufacturing Practice certificates required for pharmaceuticals to be sold in Europe.
“This is yet another important milestone towards the potential launch of Trogarzo in Europe,” said Luc Tanguay, president and CEO or Theratechnologies. More than ever, we are actively preparing for an approval in this territory to ensure that key markets will be receptive to this unique breakthrough treatment for patients with multidrug resistant HIV.”
Contact Angela Harmantas at [email protected]
Follow her on Twitter @AHarmantas